Sanofi Delays US Application for Diabetes Drug

After discussions with representatives of the Food and Drug Administration regarding its diabetes drug lixisenatide, France-based Sanofi (NYSE: SNY  ) had decided to withdraw its New Drug Application (NDA) rather than have the FDA review interim data, Sanofi announced [link opens in PDF] today.

Lixisenatide is approved for use in several countries, including Mexico, Japan, Australia, and across Europe, for treating Type 2 diabetes in adults, the company said. However, Sanofi's NDA for lixisenatide included early data on its ELIXA cardiovascular outcomes study, and there are concerns from the company that if early results of the study were to become public, it could compromise the ongoing study's integrity.

As a result, Sanofi has determined it would be more appropriate to wait for the FDA's evaluation of lixisenatide until the completion of the ELIXA study in approximately 15 months. Sanofi added in its statement that its decision to withdraw the NDA "is not related to safety issues or deficiencies in the NDA."

link


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2635132, ~/Articles/ArticleHandler.aspx, 4/20/2014 12:04:00 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement